Organization (Hospital)
Hamilton Health Sciences
ClinicalTrials.gov lists Hamilton Health Sciences as lead sponsor of 262 trials, counting the companies grouped under it. Hamilton Health Sciences itself has 76 active development programs and 68 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 13 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 16 in 2026 and about 17 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
This page covers Hamilton Health Sciences and 1 company grouped under it: 262 lead-sponsored trials (241 its own, 21 in the grouped companies) and 2 legal-entity registrations (1 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| McMaster Children's Hospital | 21 | 1 |
Disease areas (316)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 23 |
| Hemorrhage | 22 |
| Stroke | 16 |
| Fractures, Bone | 15 |
| Atrial Fibrillation | 14 |
Showing 5 of 316 disease areas.
Trials by start year as sponsor or collaborator (31)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 13 |
| 2025 | 15 |
| 2024 | 20 |
| 2023 | 15 |
| 2022 | 11 |
| 2021 | 20 |
| 2020 | 18 |
| 2019 | 23 |
| 2018 | 16 |
| 2017 | 22 |
Showing 10 of 31 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 16 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 111 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (76)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Tranexamic Acid Injectable Product | Hemorrhage | Phase 3 | 1 |
| Desmopressin Injectable Solution | Acute Kidney Injury | Phase 3 | 1 |
| Desmopressin Injectable Solution | Renal Insufficiency, Chronic | Phase 3 | 1 |
| Desmopressin Injectable Solution | Hemorrhage | Phase 3 | 1 |
| Tranexamic Acid Injectable Product | Renal Insufficiency, Chronic | Phase 3 | 1 |
Showing 5 of 76 active programs.
Approved assets (68)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| VANCOMYCIN | 4 |
| Cefazolin | 2 |
| (Arm Closed) Enoxaparin | 2 |
| Lidocaine | 2 |
| Bupivacaine-EPINEPHrine 0.5%-1:200,000 Injectable Solution | 1 |
Showing 5 of 68 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 43% hit target (n=40) | 22% on time (n=41) |
Journals published in (537)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMJ open | 33 |
| The New England journal of medicine | 26 |
| Lancet (London, England) | 24 |
| JAMA | 18 |
| Pilot and feasibility studies | 18 |
Showing 5 of 537 journals.
Financing and grant events (5)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-08-13 | NIH grant | 327,984 | Reporter |
| 2024-06-11 | NIH grant | 334,679 | Reporter |
| 2023-09-20 | NIH grant | 332,452 | Reporter |
| 2023-07-24 | NIH grant | 325,999 | Reporter |
| 2023-03-02 | NIH grant | 325,999 | Reporter |
Organization relationships (98)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| McMaster University | Co sponsors trial with | 20 |
| The Hospital for Sick Children | Co sponsors trial with | 10 |
| Children's Hospital of Eastern Ontario | Co sponsors trial with | 9 |
| Hamilton Academic Health Sciences Organization | Co sponsors trial with | 5 |
| St. Justine's Hospital | Co sponsors trial with | 5 |
Showing 5 of 98 relationships.
Latest dated events (433)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 433 events.
Biomarker capability evidence (247)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABO | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| AGT | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 247 evidence rows.
Biomarkers this organization publishes on (119)
Shown in this order: most publications first.
Showing 5 of 119 biomarkers.
On Scientist.com
Hamilton Health Sciences is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with Hamilton Health Sciences on Scientist.com
For prices, more details, or to contact Hamilton Health Sciences, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.